Sanofi-Aventis SA has reportedly offered between $67 and $70 per share for Genzyme Corp in what amounts to a friendly acquisition proposal, according to a report in the 3 August 2010 edition of the Wall Street Journal.
An antiretroviral-based microbicide that includes the drug, tenofovir, has been shown in a Phase 2b trial to moderately protect women against sexually-transmitted HIV. The trial results were released at an international AIDS conference in Vienna.
.
BTC Plc expects to report data from a Phase 2a study of its oral multiple sclerosis treatment, Pleneva, in the first half of 2011. Meanwhile, it is making plans to take over US sales from Nycomed of two emergency care products in October, 2010.
A group of international scientists has identified three monoclonal antibodies, the strongest of which neutralises more than 90% of the circulating strains of the human immunodeficiency virus (HIV). The findings were reported in the journal Science.
The Global Alliance for TB Drug Development has reached an agreement with the Geneva-based Drugs for Neglected Diseases initiative (DNDi) under which it will grant royalty-free rights to DNDi to develop drugs against neglected diseases.
AstraZeneca Plc and the technology transfer arm of the UK Medical Research Council have reached an agreement to share their respective compound libraries in order to increase the prospect of finding new treatments for serious diseases.
A team of researchers in the US has reported that the CD95 receptor promotes tumour growth, a finding that advances work done at the German Cancer Research Center in Heidelberg, and at its spin-out, Apogenix GmbH.
Sanofi-Aventis SA said that it has entered into a research alliance with the Massachusetts Institute of Technology’s Center for Biomedical Innovation that will support the translation of basic research into new healthcare products.
The US National Institute of Allergy and Infectious Diseases has awarded a grant to a San Diego, California-based company to progress new technology for fighting S. aureus by disrupting a signalling process called quorum sensing.
Scientists at the J. Craig Venter Institute in the US have reported the successful construction of a self-replicating, synthetic bacterial cell, technology that could have future application to pharmaceuticals.